Humana Inc.
HUM
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 29, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
41.4% upsideUndervalued by 41.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $43.30 Billion |
|---|---|
| Enterprise Value | $52.34 Billion |
| Dividend Yield | $3.54 (0.98%) |
| Earnings per Share | $9.87 |
| Beta | 0.77 |
| Outstanding Shares | 120,332,000 |
Return
| Return on Equity | 6.08% |
|---|---|
| Return on Assets | 2.04% |
| Return on Invested Capital | 5.88% |
Valuation & Multiples
| P/E Ratio | 38.41 |
|---|---|
| PEG | -823.72 |
| Price to Sales | 0.32 |
| Price to Book Ratio | 2.34 |
| Enterprise Value to Revenue | 0.38 |
| Enterprise Value to EBIT | 26.36 |
| Enterprise Value to Net Income | 46 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 0.75 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8862▲ 21.80% |
|---|---|
| Total Calls | 4,035,562▼ 18.98% |
| Total Puts | 3,576,458▲ 7.45% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 95.76%▼ 4.24% |
|---|---|
| Total Invested | $19.97B▼ 35.31% |
| Investors Holding | 833▼ 89.00% |
ESG Score
No data
About Humana Inc.
CEO: Bruce Broussard Relevant Senate Committees
This is the most powerful committee for Humana, controlling taxation, trade, and entitlement spending, including the structure and reimbursement rates for Medicare and Medicaid, directly shaping Humana's financial performance and regulatory environment.
This committee allocates federal discretionary spending, directly determining the precise cash flow and funding levels for government healthcare programs (Medicare, Medicaid) that are fundamental to Humana's revenue.
This committee has direct oversight of health policy, including labor laws which affect home healthcare workers, and overall regulations impacting the healthcare and biotech sectors crucial for Humana.
Humana's core business heavily serves older Americans through Medicare Advantage and home health. This committee's hearings on drug pricing and long-term care directly create headline risk and influence policy relevant to Humana's operations.
Humana, as a major healthcare provider and home health service, is directly impacted by VA funding decisions and policies related to veterans' healthcare and benefits.